

Bouke P C Hazenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8055761/publications.pdf>

Version: 2024-02-01

101
papers

6,996
citations

94269

37
h-index

58464

82
g-index

106
all docs

106
docs citations

106
times ranked

6242
citing authors

#	ARTICLE	IF	CITATIONS
1	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 8-13.	1.4	24
2	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 50-55.	1.4	28
3	Muscle mass versus body mass index as predictor of adverse outcome. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 517-518.	2.9	3
4	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
5	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
6	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
7	Protease resistance of <i>ex vivo</i> amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 243-251.	1.4	25
8	Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?. Journal of Nuclear Cardiology, 2020, 27, 1774-1784.	1.4	14
9	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€”Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
10	99mTc-aprotinin imaging in cardiac amyloidosis. Make an old tool new again?. Journal of Nuclear Cardiology, 2020, 27, 1155-1157.	1.4	1
11	Coexistence of wild type and hereditary ATTR amyloidosis in one family. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 71-72.	1.4	0
12	Causes of AA amyloidosis: a systematic review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 1-12.	1.4	69
13	A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 119-127.	1.4	1
14	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	1.2	2
15	Morphological and primary structural consistency of fibrils from different AA patients (common) Tj ETQq1 1 0.784314 rgBT /Overlock Journal of the International Society of Amyloidosis, 2019, 26, 164-170.	1.4	19
16	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
17	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107

#	ARTICLE	IF	CITATIONS
19	Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 220.	1.2	6
20	Time for new imaging and therapeutic approaches in cardiac amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1402-1406.	3.3	12
21	Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. <i>Nature Communications</i> , 2019, 10, 1104.	5.8	113
22	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27
23	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. <i>European Heart Journal</i> , 2019, 40, 1287-1293.	1.0	39
24	Imaging cardiac innervation in amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 174-187.	1.4	21
25	Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1945-1955.	3.3	96
26	Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma. <i>Thrombosis and Haemostasis</i> , 2018, 118, 471-479.	1.8	6
27	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2018, 121, 107-112.	0.7	22
28	Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 227-233.	1.4	7
29	Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome. <i>Rheumatology</i> , 2018, 57, 1812-1821.	0.9	28
30	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. <i>Journal of Proteome Research</i> , 2018, 17, 4072-4084.	1.8	5
31	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). <i>Cardiovascular Pathology</i> , 2017, 29, 19-22.	0.7	3
32	Diagnostic accuracy of new indirect ELISAs for free light-chain quantification in fat tissue of patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 46-47.	1.4	0
33	Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma. <i>American Journal of Kidney Diseases</i> , 2017, 69, 546-549.	2.1	12
34	Clinical and 123I-SAP scintigraphy findings in three members from a family affected by AGel amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 155-156.	1.4	0
35	First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. <i>Current Opinion in Neurology</i> , 2016, 29, S14-S26.	1.8	179
36	The Prevalence and Management of Systemic Amyloidosis in Western Countries. <i>Kidney Diseases (Basel)</i> , 2016, 1, 1-10.	1.2	90

#	ARTICLE	IF	CITATIONS
37	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2016, 133, 2404-2412.	1.6	1,335
38	Long-term follow-up after surgery in localized laryngeal amyloidosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2613-2620.	0.8	31
39	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed AL Amyloidosis. <i>Blood</i> , 2016, 128, 4628-4628.	0.6	1
40	Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. <i>Scientific Reports</i> , 2015, 5, 16474.	1.6	62
41	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. <i>Haematologica</i> . 2015, 100, 677-682.	1.7	18
42	Transthyretin-Derived (ATTR) Amyloidotic Cardiomyopathy After Receiving a Domino Liver Allograft. <i>Circulation</i> , 2015, 132, e216-7.	1.6	8
43	Sensitive and rapid assessment of amyloid by oligothiophene fluorescence in subcutaneous fat tissue. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 19-25.	1.4	28
44	Nuclear imaging for cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2015, 20, 145-154.	1.7	15
45	Fat Tissue Analysis in the Management of Patients with Systemic Amyloidosis. <i>Current Clinical Pathology</i> , 2015, , 229-248.	0.0	1
46	Imaging of the Autonomic Nervous System in Cardiac Amyloidosis. , 2015, , 321-335.		0
47	Bone scintigraphy with ^{99m} Tc-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 35-44.	1.4	129
48	Cardiac diphosphonate uptake. <i>Heart</i> , 2014, 100, 1192-1192.	1.2	0
49	Additional diagnostic value of SPECT/CT to planar Iodine-123 labeled serum amyloid P component scintigraphy in a patient with pulmonary nodular amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 131-133.	1.4	1
50	Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1095-1101.	3.3	49
51	Fluorine-18 labeled fluorodeoxyglucose PET useful for therapy monitoring in localized AL amyloidosis?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 135-137.	1.4	1
52	Amyloidosis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 323-345.	0.8	122
53	Echocardiographic features of an atypical presentation of rapidly progressive cardiac amyloidosis. <i>World Journal of Cardiology</i> , 2013, 5, 154.	0.5	0
54	Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 208-211.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 56-57.	1.4	1
56	123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1609-1617.	3.3	49
57	Fat Tissue Analysis in the Management of Patients with Systemic Amyloidosis. , 2012, , 191-207.		3
58	Lower Serum Paraoxonase-1 Activity Is Related to Higher Serum Amyloid A Levels in Metabolic Syndrome. <i>Archives of Medical Research</i> , 2011, 42, 219-225.	1.5	45
59	In memoriam Enno Mandema, MD (1921-2010). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 249-250.	1.4	1
60	Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. <i>Rheumatology</i> , 2011, 50, 1925-1926.	0.9	23
61	Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. <i>Arthritis Care and Research</i> , 2010, 62, 296-301.	1.5	30
62	Laryngeal presentation of systemic apolipoprotein Aâ€œderived amyloidosis. <i>Laryngoscope</i> , 2009, 119, 608-615.	1.1	24
63	Improvement of lipid profile is accompanied by atheroprotective alterations in highâ€œdensity lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1324-1330.	6.7	101
64	Erythrocyte sedimentation rate, Câ€œreactive protein level, and serum amyloid A protein for patient selection and monitoring of antiâ€œtumor necrosis factor treatment in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1484-1490.	6.7	112
65	Nuclear imaging in cardiac amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 702-714.	3.3	84
66	Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 133-141.	1.4	19
67	Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. <i>Haematologica</i> , 2009, 94, 1094-1100.	1.7	32
68	Novel treatments for systemic amyloidosis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 171-188.	0.3	1
69	SjÃ¶gren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. <i>Arthritis and Rheumatism</i> , 2008, 58, 1992-1999.	6.7	61
70	Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. <i>Journal of Clinical Investigation</i> , 2008, 118, 3208-18.	3.9	205
71	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). <i>Blood</i> , 2008, 112, 163-163.	0.6	2
72	High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. <i>New England Journal of Medicine</i> , 2008, 358, 92; author reply 92-3.	13.9	1

#	ARTICLE	IF	CITATIONS
73	Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 221-226.	1.4	23
74	Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 865-872.	2.8	45
75	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 133-140.	1.4	35
76	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 356, 2349-2360.	13.9	240
77	Genetic microheterogeneity of human transthyretin detected by IEF. <i>Electrophoresis</i> , 2007, 28, 2053-2064.	1.3	37
78	Increased plasmin- α 2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1139-1142.	1.9	36
79	Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. <i>American Journal of Medicine</i> , 2006, 119, 355.e15-355.e24.	0.6	129
80	Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. <i>Arthritis and Rheumatism</i> , 2006, 54, 2015-2021.	6.7	193
81	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. <i>American Journal of Hematology</i> , 2005, 79, 319-328.	2.0	1,179
82	Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2004, 11, 44-49.	1.4	20
83	Laryngeal Amyloidosis: Localized versus Systemic Disease and Update on Diagnosis and Therapy. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2004, 113, 741-748.	0.6	75
84	Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. <i>European Heart Journal</i> , 2002, 23, 157-161.	1.0	40
85	Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1212-1217.	0.4	29
86	Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 42-47.	0.5	36
87	AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 165-174.	1.4	51
88	Where has secondary amyloid gone?. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 577-579.	0.5	67
89	A homozygous M694V mutation of the MEFV gene in a patient with periodic fever and thoracic pain. <i>Netherlands Journal of Medicine</i> , 2000, 56, 21-24.	0.6	0
90	Transthyretin Val71Ala mutation in a Dutch family with familial amyloidotic polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 218-221.	1.4	6

#	ARTICLE	IF	CITATIONS
91	A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 96-102.	0.5	45
92	The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1998, 5, 193-199.	1.4	10
93	A Dutch kindred with familial amyloidotic polyneuropathy associated with the trans thy retin Cys 114 mutant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1997, 4, 112-117.	1.4	6
94	Annual evaluation of hip joints and hands for radiographic signs of A β 2M-amyloidosis in long-term hemodialysis patients. <i>Skeletal Radiology</i> , 1994, 23, 421-7.	1.2	6
95	Clinical and therapeutic aspects of AA amyloidosis. <i>Bailliere's Clinical Rheumatology</i> , 1994, 8, 661-690.	1.0	55
96	Acute neuromyopathy after colchicine treatment.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 1267-1268.	0.5	8
97	Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. <i>Critical Care Medicine</i> , 1992, 20, 185-192.	0.4	194
98	Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1091, 405-408.	1.9	105
99	Monoclonal Antibody Based ELISA for Human SAA. , 1991, , 898-901.		9
100	Crp and SAA Serum Levels in Chronic Active Hepatitis. , 1991, , 825-826.		0
101	The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 1988, 155, 112-117.	1.0	252